BEHAVIORAL PHARMACOLOGY OF ANTIDEPRESSANT AND ANXIOLYTIC AGENTS
Keywords:
behavioral pharmacology; antidepressants; anxiolytics; SSRIs; benzodiazepines; ketamine; GABA-A receptor; serotonin; anxiety; depressionAbstract
Behavioral pharmacology provides an essential bridge between molecular drug action and clinically meaningful changes in mood, anxiety, motivation, stress coping, and cognition. This structured review synthesizes evidence on the behavioral and mechanistic profiles of major antidepressant and anxiolytic drug classes, with emphasis on monoaminergic antidepressants, benzodiazepines and other GABAergic modulators, 5-HT1A agonists, and rapid-acting glutamatergic antidepressants. A targeted literature synthesis was conducted using peer-reviewed international sources, prioritizing contemporary mechanistic reviews, translational studies, and methodological analyses of behavioral models. The evidence indicates that selective serotonin reuptake inhibitors (SSRIs) and serotonin–norepinephrine reuptake inhibitors (SNRIs) exert delayed behavioral effects that depend on downstream neuroadaptation, while benzodiazepines produce rapid anxiolysis through positive allosteric modulation of GABA-A receptors but are limited by sedation, tolerance, and dependence. Ketamine and esketamine demonstrate a distinct rapid-acting profile involving NMDA-receptor blockade, AMPA-dependent synaptic potentiation, BDNF-related plasticity, and network-level resetting. Preclinical behavioral assays remain valuable for screening but require careful interpretation because single tests may capture coping, locomotion, exploration, or reward processes rather than discrete psychiatric diagnoses. The most informative strategy combines multiple behavioral domains with mechanistic biomarkers and clinically relevant outcome measures. Future behavioral pharmacology is likely to rely on circuit-resolved phenotyping, digital behavioral markers, sex-aware models, and mechanism-based patient stratification to improve translation from experimental findings to individualized therapy.
